Paul Tudor Jones Immunity Bio, Inc. Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$4.82 - $9.15 $487,041 - $924,570
101,046 New
101,046 $638,000
Q1 2023

May 15, 2023
BUY
$1.35 - $4.78 $265,188 - $938,964
196,436 New
196,436 $358,000
Q2 2022

Aug 15, 2022
BUY
$2.68 - $6.14 $254,975 - $584,159
95,140 New
95,140 $354,000

Others Institutions Holding IBRX

# of Institutions
202
Shares Held
70M
Call Options Held
1.68M
Put Options Held
1.31M
View Full List

About ImmunityBio, Inc.

IBRX Quotes by TradingView
  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.8B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email